

Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.



LifeTech Scientific Corporation

先健科技公司

(Incorporated in the Cayman Islands with limited liability)

(Stock Code: 1302)

IBS ANGEL™ IRON BIORESORBABLE SCAFFOLD SYSTEM WAS APPROVED FOR REGISTRATION IN MALAYSIA

This announcement is made by LifeTech Scientific Corporation (the “**Company**”, together with its subsidiaries, the “**Group**”) on a voluntary basis to provide its shareholders and potential investors with information in relation to the latest business and new product development of the Group.

The board (the “**Board**”) of directors (the “**Directors**”) of the Company is pleased to announce that on 8 June 2021, the Group’s self-developed IBS Angel™ Iron Bioresorbable Scaffold System (“**IBS Angel™**” or the “**Product**”) has been granted with Medical Device Registration Certificate in Malaysia.

IBS Angel™ consists of iron bioresorbable stent and delivery system for the purpose of improving the lumen diameter of the pulmonary blood vessels of patients who require stent treatment. The scaffold matrix is made of high-strength nitrided iron tube. The design of having multiple breakpoints on the scaffold strut ensures that the scaffold could be disintegrated soon after the effective support period, without constraining the growth of blood vessels. The scaffold can be degraded and finally absorbed by human tissue. The innovative material and structure design can ensure reasonable absorption profile of the scaffold.

Compared with permanent stent currently available on the market, the Product has unique advantages in treating newborns and infants with insufficient blood supply in pulmonary blood vessels. As children develop, the permanent stent will restrain the growth of their blood vessels, resulting in restenosis, which requires treatment by means of a second intervention or even surgery to resolve the above problems, causing additional burden on such children’s body. The Product, meanwhile, will

fundamentally resolve the aforementioned problems due to its degradability. Furthermore, IBS Angel™ has a thin-strut design compatible with 4F sheath (inner diameter ~1.35mm) as a minimum, which is especially suitable for small vessels of newborns.

At present, IBS Angel™ has been approved for sale in Malaysia, being the only absorbable stent product suitable for children in the world, benefiting patients. At the same time, the Product is actively undergoing CE and domestic registration, and is expected to become the first iron-based absorbable stent to be marketed in the EU and China.

By order of the Board
LifeTech Scientific Corporation
XIE Yuehui
*Executive Director, Chairman and
Chief Executive Officer*

Hong Kong, 9 June 2021

As at the date of this announcement, the Board comprises Mr. XIE Yuehui and Mr. LIU Jianxiong being executive Directors; Mr. JIANG Feng being non-executive Director; and Mr. LIANG Hsien Tse Joseph, Mr. WANG Wansong and Mr. ZHOU Luming being independent non-executive Directors.